7 Jul 2022
The two German vaccine competitors are heading to court over a legal dispute concerning BioNTech's coronavirus vaccine. CureVac has called for "fair compensation."
2 Jul 2021
CureVac's jab was found to be 48% effective across all ages, with an efficacy far lower than expected. The number is slightly higher at 53% among 18 to 60-year-olds. Follow DW for the latest.
19 Jun 2021
The German pharma company cited "the unprecedented context of at least 13 variants" in explaining why its vaccine fell short of expectations in an interim analysis.
17 Jan 2021
Tesla CEO Elon Musk praised CureVac's innovative work on vaccines during a visit to its HQ in September. The firm will now team up with pharma giant Bayer to develop its coronavirus vaccine candidate.
6 Sep 2020
The billionaire is visiting Germany to explore a potential coronavirus vaccine made by CureVac. The biotechnology firm, which Germany has a direct stake in, is in the advanced stages of developing a vaccine candidate.
18 Aug 2020
German coronavirus vaccine developer CureVac says its New York share market debut has netted more than €180 million. Its shares sold at the top end in Friday's placing on the Nasdaq exchange.